Business Context and Reporting Period
Ligand Pharmaceuticals Inc. (Ligand) is a biotechnology company focused on drug discovery and early-stage development. This Form 10-Q covers the quarterly period ended March 31, 2009. The company's revenue model relies heavily on royalties from partners (King Pharmaceuticals for AVINZA and GlaxoSmithKline for PROMACTA) and collaborative research agreements. In December 2008, Ligand acquired Pharmacopeia, Inc., a clinical-stage biopharmaceutical company, to expand its pipeline.
Key Financial Metrics
| Metric (in thousands) | Q1 2009 | Q1 2008 |
|---|---|---|
| Total Revenues | $9,470 | $4,874 |
| Net Loss | $(5,116) | $(3,933) |
| Loss from Continuing Operations | $(7,482) | $(9,717) |
| Net Cash Used in Operating Activities | $(24,121) | $(9,399) |
| Cash and Cash Equivalents (Ending) | $4,920 | $59,543 |
| Short-term Investments | $47,684 | $51,918 |
| Total Assets | $139,587 | $171,448 |
| Accumulated Deficit | $(684,715) | $(679,626) |
Liquidity: As of March 31, 2009, available cash, cash equivalents, and short-term investments totaled approximately $52.6 million. Working capital was $14.8 million.
Material Changes vs. Prior Period
- Revenue Increase: Total revenues increased 94% to $9.5 million, driven by $6.7 million in new collaborative research and development revenues (primarily from the Pharmacopeia acquisition) and $2.7 million in royalties. Royalty revenue specifically decreased 44% due to a contractual reduction in the AVINZA royalty rate from 15% to 5%.
- Expense Fluctuations: Research and Development (R&D) expenses increased 46% to $10.5 million, largely due to costs associated with servicing collaboration agreements acquired from Pharmacopeia. General and Administrative (G&A) expenses decreased 32% to $6.8 million, primarily due to the absence of $4.1 million in facility exit costs incurred in Q1 2008, partially offset by legal settlement costs in Q1 2009.
- Cash Flow Deterioration: Net cash used in operating activities increased significantly to $24.1 million (from $9.4 million in 2008). This was driven by a $8.5 million non-recurring litigation settlement payment to Rockefeller University and the Salk Institute, as well as a decrease in accounts payable and accrued liabilities.
- Discontinued Operations: The company recognized a pre-tax gain of $2.4 million from discontinued operations (AVINZA and Oncology product lines), compared to $5.8 million in the prior year. The 2008 gain included a significant release of escrow funds.
Outlook, Risks, and Management Commentary
- Liquidity Outlook: Management believes current cash, investments, and future royalty revenues are sufficient to fund operations for at least the next twelve months. However, the company faces risks related to the volatility of capital markets and the potential need for additional financing.
- Key Milestones: In Q1 2009, Ligand earned a milestone from Pfizer (paid via stock return) and a $0.6 million milestone from Wyeth for the European approval of bazedoxifene (CONBRIZA). GSK's PROMACTA received FDA approval in late 2008, generating tiered royalties.
- Legal Resolutions: In April 2009, the SEC completed its investigation into Ligand's 2002-2004 financial restatement and did not recommend enforcement action. Consequently, Ligand received $10.3 million from a restricted indemnity account. The company also settled litigation with The Rockefeller University for $5.0 million upfront plus future royalties.
- Investment Risk: Ligand holds a $5.0 million commercial paper investment from Golden Key Ltd. that is in default. Management estimates a recovery of only $1.6 million and recorded an impairment loss of $0.1 million in Q1 2009.
- Co-Promotion Liability: Ligand remains legally liable to Organon for co-promotion termination payments (estimated at $58.0 million undiscounted) in the event King Pharmaceuticals defaults, although King has assumed the obligation.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $24.1 million quarterly cash burn given the $52.6 million liquidity position and the reliance on royalty income which is subject to partner sales performance.
- Golden Key Exposure: Confirm the status of the $5.0 million defaulted commercial paper investment and the likelihood of the estimated $1.6 million recovery.
- AVINZA Royalty Sensitivity: Assess the impact of the reduced 5% royalty rate on AVINZA sales and the risk of generic competition (Actavis ANDA filing) on future revenue streams.
- Pharmacopeia Integration: Monitor the integration of Pharmacopeia's pipeline and the realization of the $15.0 million contingent value rights (CVRs) which are not currently recognized as probable.
- Legal Contingencies: Review the terms of the Rockefeller University settlement and the potential for future royalty payments to be shared, as well as the status of the Pharmacopeia class action settlement.